Toggle Main Menu Toggle Search

Open Access padlockePrints

3D manufactured islet micro-tissues for the treatment of type-1 diabetes

Lookup NU author(s): Alexander Popov, Dr Bill ScottORCiD, Dr Jinju Chen, Professor James Shaw, Professor Kenneth Dalgarno, Dr Ana Ferreira-DuarteORCiD


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Type-1 diabetes mellitus is defined by the inability to control systemic glucose levels, due to an autoimmune destruction of the insulin-producing β-cells. Treatment involves routine glucose monitoring and insulin infusion. However, some patients with hypoglycaemia unawareness may require pancreas or islet transplantation. Islet transplantation is a minimally invasive 'micro-tissue' therapy aimed at reducing hyperglycaemia and eliminating severe hypoglycaemia. This is achieved by infusing islets of Langerhans into the portal vein; where they engraft in the liver. Major limitations of islet transplantation include the need for life-long immunosuppression and a high tissue demand. This work aims to overcome these restrictions and improve engraftment by applying 3D bioprinting to standardise islet size and ECM composition with the goal to reduce tissue loss immediately post transplantation and improve engraftment. A tri-component ‘bioink’ hydrogel was developed and investigated using collagen, alginate and fibrin (CAF), at three collagen concentrations (0.5%, 1% and 2.5%), for β-cell replacement therapy to treat type-1 diabetes.

Publication metadata

Author(s): Popov AA, Montalbano G, Scott WE, Chen J, Shaw JAM, Dalgarno K, Ferreira-Duarte AM

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: TERMIS-EU 2016 Conference

Year of Conference: 2016

Pages: 175-175

Online publication date: 28/06/2016

Acceptance date: 01/01/2016

ISSN: 1473-2262

Publisher: eCM


DOI: 10.22203/eCM

Series Title: